Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995241 | 0.85 | LMNA (0.46) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL2739055 | 0.81 | MAPT (0.46) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL6663539 | 0.78 | — | — | |
| SCHEMBL10498542 | 0.78 | LMNA (0.70) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL2739056 | 0.77 | KDM4E (0.53) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL2739057 | 0.77 | MAPT (0.49) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL20019684 | 0.75 | MAPT (0.47) | LMNAMAPTKDM4EGAANPC1 | |
| SCHEMBL28473908 | 0.75 | LMNA (0.44) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL219990 | 0.73 | KDM4E (0.41) | LMNAMAPTKDM4EGAAHTT | |
| SCHEMBL219989 | 0.73 | LMNA (0.45) | LMNAMAPTKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1778252-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | Barbeau, Donald L. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020573-A2 | NONCARDIOTOXIC PHARMACEUTICAL COMPOUNDS | BARBEAU DONALD L (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | B&G PARTNERS, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | KCNN3, TNNI3, TNNT2 | LMNA 204/4885MAPT 2361/4885KDM4E 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.